Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin

Maddalena Barba, Laura Pizzuti, Isabella Sperduti, Clara Natoli, Teresa Gamucci, Domenico Sergi, Luigi Di Lauro, Luca Moscetti, Fiorentino Izzo, Massimo Rinaldi, Lucia Mentuccia, Angela Vaccaro, Laura Iezzi, Antonino Grassadonia, Andrea Michelotti, Elisabetta Landucci, Letizia Perracchio, Edoardo Pescarmona, Franco Di Filippo, Antonio Giordano & 2 others Marcello Maugeri-Saccà, Patrizia Vici

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Eribulin has shown survival advantage and manageable toxicity in heavily pre-treated metastatic breast cancer (mBC). We assessed whether body mass index (BMI) impacts treatment outcomes in 101 patients treated with eribulin at six Italian Oncologic Centers. BMI was addressed as a categorical variable (18.5-24.9 vs. at least 25). Clinical benefit rate (CBR) was assessed overall and in subgroups defined by BMI, line of therapy (LOT), and hormone receptor (HR) status. Analysis of CBR by LOT and HR status were further stratified by BMI. Survival curves were compared using the Kaplan-Meier method and log-rank test. Predictors of survival were tested in Cox models. Patients treated with eribulin as third line showed greater CBR when their BMI was in the lowest category (77.8 vs. 58.1%, P=0.03). Median progression free survival (PFS) and overall survival (OS) in normal and overweight patients were 4 (95% CI, 3-5) versus 3 (2.1-4) months, P=0.02 and 13 (11-15) versus 12 (6-18) months, P=0.96, respectively. Median PFS and OS in estrogen receptor (ER) positive and negative tumours were 4 (3-5) versus 3 (2-4) months, P=0.005 and 14 (10-18) versus 7 (4-10), P=0.02, respectively. In multivariate analyses, BMI impacted PFS at a nearly significant extent (P=0.05), while ER expression significantly affected PFS and OS (P=0.01 and 0.02, respectively). No relevant findings emerged concerning toxicity. We found evidence of greater efficacy of eribulin in leaner mBC patients, particularly if given as third line and in ER positive tumors. Further studies are warranted to confirm our findings.

Original languageEnglish
Pages (from-to)986-991
Number of pages6
JournalJournal of Cellular Physiology
Volume231
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

eribulin
Body Mass Index
Estrogen Receptors
Breast Neoplasms
Disease-Free Survival
Survival
Toxicity
Tumors
Hormones
Proportional Hazards Models
Neoplasms
Multivariate Analysis

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. / Barba, Maddalena; Pizzuti, Laura; Sperduti, Isabella; Natoli, Clara; Gamucci, Teresa; Sergi, Domenico; Di Lauro, Luigi; Moscetti, Luca; Izzo, Fiorentino; Rinaldi, Massimo; Mentuccia, Lucia; Vaccaro, Angela; Iezzi, Laura; Grassadonia, Antonino; Michelotti, Andrea; Landucci, Elisabetta; Perracchio, Letizia; Pescarmona, Edoardo; Di Filippo, Franco; Giordano, Antonio; Maugeri-Saccà, Marcello; Vici, Patrizia.

In: Journal of Cellular Physiology, Vol. 231, No. 5, 01.05.2016, p. 986-991.

Research output: Contribution to journalArticle

Barba, M, Pizzuti, L, Sperduti, I, Natoli, C, Gamucci, T, Sergi, D, Di Lauro, L, Moscetti, L, Izzo, F, Rinaldi, M, Mentuccia, L, Vaccaro, A, Iezzi, L, Grassadonia, A, Michelotti, A, Landucci, E, Perracchio, L, Pescarmona, E, Di Filippo, F, Giordano, A, Maugeri-Saccà, M & Vici, P 2016, 'Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin', Journal of Cellular Physiology, vol. 231, no. 5, pp. 986-991. https://doi.org/10.1002/jcp.25213
Barba, Maddalena ; Pizzuti, Laura ; Sperduti, Isabella ; Natoli, Clara ; Gamucci, Teresa ; Sergi, Domenico ; Di Lauro, Luigi ; Moscetti, Luca ; Izzo, Fiorentino ; Rinaldi, Massimo ; Mentuccia, Lucia ; Vaccaro, Angela ; Iezzi, Laura ; Grassadonia, Antonino ; Michelotti, Andrea ; Landucci, Elisabetta ; Perracchio, Letizia ; Pescarmona, Edoardo ; Di Filippo, Franco ; Giordano, Antonio ; Maugeri-Saccà, Marcello ; Vici, Patrizia. / Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. In: Journal of Cellular Physiology. 2016 ; Vol. 231, No. 5. pp. 986-991.
@article{325892c4cf5942bfb1b460d8fe33a3b1,
title = "Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin",
abstract = "Eribulin has shown survival advantage and manageable toxicity in heavily pre-treated metastatic breast cancer (mBC). We assessed whether body mass index (BMI) impacts treatment outcomes in 101 patients treated with eribulin at six Italian Oncologic Centers. BMI was addressed as a categorical variable (18.5-24.9 vs. at least 25). Clinical benefit rate (CBR) was assessed overall and in subgroups defined by BMI, line of therapy (LOT), and hormone receptor (HR) status. Analysis of CBR by LOT and HR status were further stratified by BMI. Survival curves were compared using the Kaplan-Meier method and log-rank test. Predictors of survival were tested in Cox models. Patients treated with eribulin as third line showed greater CBR when their BMI was in the lowest category (77.8 vs. 58.1{\%}, P=0.03). Median progression free survival (PFS) and overall survival (OS) in normal and overweight patients were 4 (95{\%} CI, 3-5) versus 3 (2.1-4) months, P=0.02 and 13 (11-15) versus 12 (6-18) months, P=0.96, respectively. Median PFS and OS in estrogen receptor (ER) positive and negative tumours were 4 (3-5) versus 3 (2-4) months, P=0.005 and 14 (10-18) versus 7 (4-10), P=0.02, respectively. In multivariate analyses, BMI impacted PFS at a nearly significant extent (P=0.05), while ER expression significantly affected PFS and OS (P=0.01 and 0.02, respectively). No relevant findings emerged concerning toxicity. We found evidence of greater efficacy of eribulin in leaner mBC patients, particularly if given as third line and in ER positive tumors. Further studies are warranted to confirm our findings.",
author = "Maddalena Barba and Laura Pizzuti and Isabella Sperduti and Clara Natoli and Teresa Gamucci and Domenico Sergi and {Di Lauro}, Luigi and Luca Moscetti and Fiorentino Izzo and Massimo Rinaldi and Lucia Mentuccia and Angela Vaccaro and Laura Iezzi and Antonino Grassadonia and Andrea Michelotti and Elisabetta Landucci and Letizia Perracchio and Edoardo Pescarmona and {Di Filippo}, Franco and Antonio Giordano and Marcello Maugeri-Sacc{\`a} and Patrizia Vici",
year = "2016",
month = "5",
day = "1",
doi = "10.1002/jcp.25213",
language = "English",
volume = "231",
pages = "986--991",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin

AU - Barba, Maddalena

AU - Pizzuti, Laura

AU - Sperduti, Isabella

AU - Natoli, Clara

AU - Gamucci, Teresa

AU - Sergi, Domenico

AU - Di Lauro, Luigi

AU - Moscetti, Luca

AU - Izzo, Fiorentino

AU - Rinaldi, Massimo

AU - Mentuccia, Lucia

AU - Vaccaro, Angela

AU - Iezzi, Laura

AU - Grassadonia, Antonino

AU - Michelotti, Andrea

AU - Landucci, Elisabetta

AU - Perracchio, Letizia

AU - Pescarmona, Edoardo

AU - Di Filippo, Franco

AU - Giordano, Antonio

AU - Maugeri-Saccà, Marcello

AU - Vici, Patrizia

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Eribulin has shown survival advantage and manageable toxicity in heavily pre-treated metastatic breast cancer (mBC). We assessed whether body mass index (BMI) impacts treatment outcomes in 101 patients treated with eribulin at six Italian Oncologic Centers. BMI was addressed as a categorical variable (18.5-24.9 vs. at least 25). Clinical benefit rate (CBR) was assessed overall and in subgroups defined by BMI, line of therapy (LOT), and hormone receptor (HR) status. Analysis of CBR by LOT and HR status were further stratified by BMI. Survival curves were compared using the Kaplan-Meier method and log-rank test. Predictors of survival were tested in Cox models. Patients treated with eribulin as third line showed greater CBR when their BMI was in the lowest category (77.8 vs. 58.1%, P=0.03). Median progression free survival (PFS) and overall survival (OS) in normal and overweight patients were 4 (95% CI, 3-5) versus 3 (2.1-4) months, P=0.02 and 13 (11-15) versus 12 (6-18) months, P=0.96, respectively. Median PFS and OS in estrogen receptor (ER) positive and negative tumours were 4 (3-5) versus 3 (2-4) months, P=0.005 and 14 (10-18) versus 7 (4-10), P=0.02, respectively. In multivariate analyses, BMI impacted PFS at a nearly significant extent (P=0.05), while ER expression significantly affected PFS and OS (P=0.01 and 0.02, respectively). No relevant findings emerged concerning toxicity. We found evidence of greater efficacy of eribulin in leaner mBC patients, particularly if given as third line and in ER positive tumors. Further studies are warranted to confirm our findings.

AB - Eribulin has shown survival advantage and manageable toxicity in heavily pre-treated metastatic breast cancer (mBC). We assessed whether body mass index (BMI) impacts treatment outcomes in 101 patients treated with eribulin at six Italian Oncologic Centers. BMI was addressed as a categorical variable (18.5-24.9 vs. at least 25). Clinical benefit rate (CBR) was assessed overall and in subgroups defined by BMI, line of therapy (LOT), and hormone receptor (HR) status. Analysis of CBR by LOT and HR status were further stratified by BMI. Survival curves were compared using the Kaplan-Meier method and log-rank test. Predictors of survival were tested in Cox models. Patients treated with eribulin as third line showed greater CBR when their BMI was in the lowest category (77.8 vs. 58.1%, P=0.03). Median progression free survival (PFS) and overall survival (OS) in normal and overweight patients were 4 (95% CI, 3-5) versus 3 (2.1-4) months, P=0.02 and 13 (11-15) versus 12 (6-18) months, P=0.96, respectively. Median PFS and OS in estrogen receptor (ER) positive and negative tumours were 4 (3-5) versus 3 (2-4) months, P=0.005 and 14 (10-18) versus 7 (4-10), P=0.02, respectively. In multivariate analyses, BMI impacted PFS at a nearly significant extent (P=0.05), while ER expression significantly affected PFS and OS (P=0.01 and 0.02, respectively). No relevant findings emerged concerning toxicity. We found evidence of greater efficacy of eribulin in leaner mBC patients, particularly if given as third line and in ER positive tumors. Further studies are warranted to confirm our findings.

UR - http://www.scopus.com/inward/record.url?scp=84956599550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956599550&partnerID=8YFLogxK

U2 - 10.1002/jcp.25213

DO - 10.1002/jcp.25213

M3 - Article

VL - 231

SP - 986

EP - 991

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 5

ER -